NYSE:RCUSBiotechs
Why Arcus Biosciences (RCUS) Is Up 9.5% After New Casdatifan Data And Pipeline Expansion
Arcus Biosciences recently reported full-year 2025 results, with revenue of US$247 million versus US$258 million in 2024 and a net loss of US$353 million, while also granting new employee equity awards under its 2020 Inducement Plan.
More importantly for the story, Arcus outlined encouraging new clinical data and expansion plans for its HIF-2α inhibitor casdatifan in kidney cancer, alongside moves into inflammatory and autoimmune diseases that could reshape how investors view its pipeline...